|
|
|
|
| LEADER |
03271nam a22004935i 4500 |
| 001 |
978-3-319-22909-6 |
| 003 |
DE-He213 |
| 005 |
20160317141214.0 |
| 007 |
cr nn 008mamaa |
| 008 |
160317s2016 gw | s |||| 0|eng d |
| 020 |
|
|
|a 9783319229096
|9 978-3-319-22909-6
|
| 024 |
7 |
|
|a 10.1007/978-3-319-22909-6
|2 doi
|
| 040 |
|
|
|d GrThAP
|
| 050 |
|
4 |
|a RC261-271
|
| 072 |
|
7 |
|a MJCL
|2 bicssc
|
| 072 |
|
7 |
|a MED062000
|2 bisacsh
|
| 082 |
0 |
4 |
|a 614.5999
|2 23
|
| 245 |
1 |
0 |
|a Novel Biomarkers in the Continuum of Breast Cancer
|h [electronic resource] /
|c edited by Vered Stearns.
|
| 250 |
|
|
|a 1st ed. 2016.
|
| 264 |
|
1 |
|a Cham :
|b Springer International Publishing :
|b Imprint: Springer,
|c 2016.
|
| 300 |
|
|
|a XIX, 279 p. 34 illus., 4 illus. in color.
|b online resource.
|
| 336 |
|
|
|a text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a computer
|b c
|2 rdamedia
|
| 338 |
|
|
|a online resource
|b cr
|2 rdacarrier
|
| 347 |
|
|
|a text file
|b PDF
|2 rda
|
| 490 |
1 |
|
|a Advances in Experimental Medicine and Biology,
|x 0065-2598 ;
|v 882
|
| 505 |
0 |
|
|a 1 Genomic Biomarkers for Cancer Risk -- 2 Epigenetic Biomarkers of Breast Cancer Risk: Across the Breast Cancer Prevention Continuum -- 3 Incorporating Biomarkers in Studies of Chemoprevention -- 4 Breast Molecular Profiling and Radiotherapy Considerations -- 5 Prognostic and Predictive Biomarkers of Endocrine Responsiveness For Estrogen Receptor Positive Breast Cancer -- 6 Biomarkers for predicting response to Anti-HER2 Agents -- 7 Intratumor Heterogeneity in Breast Cancer -- 8 Intratumor Heterogeneity in Breast Cancer -- 9 Pharmacogenetic Predictors of Response -- 10 Metabolomics in Breast Cancer: Current Status and Perspectives -- 11 Circulating Tumor Cells -- 12 Circulating Plasma Tumor DNA.
|
| 520 |
|
|
|a This volume provides a comprehensive review of established and novel biomarkers across the continuum of breast cancer. The volume covers topics related to breast cancer risk and prevention, prediction of response to today’s standard therapies, and markers capable of influencing treatment decisions in the near future. Chapter authors combine their wide-ranging expertise to review the current status of the biomarker and to offer their individual perspectives on how biomarkers may be used in future treatments and research. Breast cancer continues to be the most common malignancy diagnosed in women in the Western world. While there are multiple treatment approaches for breast cancer, today more than ever we recognize that each tumor is unique. The challenge ahead is to consider how to best use validated and novel biomarkers to select the most appropriate treatment for individual patients.
|
| 650 |
|
0 |
|a Medicine.
|
| 650 |
|
0 |
|a Cancer research.
|
| 650 |
|
0 |
|a Human genetics.
|
| 650 |
|
0 |
|a Oncology.
|
| 650 |
1 |
4 |
|a Biomedicine.
|
| 650 |
2 |
4 |
|a Cancer Research.
|
| 650 |
2 |
4 |
|a Oncology.
|
| 650 |
2 |
4 |
|a Human Genetics.
|
| 700 |
1 |
|
|a Stearns, Vered.
|e editor.
|
| 710 |
2 |
|
|a SpringerLink (Online service)
|
| 773 |
0 |
|
|t Springer eBooks
|
| 776 |
0 |
8 |
|i Printed edition:
|z 9783319229089
|
| 830 |
|
0 |
|a Advances in Experimental Medicine and Biology,
|x 0065-2598 ;
|v 882
|
| 856 |
4 |
0 |
|u http://dx.doi.org/10.1007/978-3-319-22909-6
|z Full Text via HEAL-Link
|
| 912 |
|
|
|a ZDB-2-SBL
|
| 950 |
|
|
|a Biomedical and Life Sciences (Springer-11642)
|
